Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder

Journal of Clinical Psychiatry

Volumn 66, Issue 6, 2005, Pages 686-692

  Delgado, Pedro L ^a   Brannan, Stephen K ^b,g   Mallinckrodt, Craig H ^b   Tran, Pierre V ^b   McNamara, Robert K ^c   Wang, Fujun ^b   Watkin, John G ^b   Detke, Michael J ^b,d,e,f  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MCLEAN HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g Cyberonics Inc   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DULOXETINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO;

ANALYTIC METHOD; ARIZONA SEXUAL EXPERIENCE SCALE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GENDER; HUMAN; INCIDENCE; MAJOR DEPRESSION; POOLED DATA ANALYSIS; POST HOC ANALYSIS; PRIORITY JOURNAL; RATING SCALE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION;

EID: 21744457235     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0603     Document Type: Article

References (41)

1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-544
2. Baldwin DS. Depression and sexual dysfunction. Br Med Bull 2001;57:81-99
3. Mathew RJ, Weinman ML. Sexual dysfunctions in depression. Arch Sex Behav 1982;11:323-328
4. Angst J. Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol 1998;13(suppl 6):S1-S4
5. Kennedy SH, Dickens SE, Eisfeld BS, et al. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999;56: 201-208
6. Bonierbale M, Lancon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003;19:114-124
7. Araujo AB, Durante R, Feldman HA, et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998;60: 458-465
8. Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 2001;62(suppl 3):22-34
9. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19:67-85
10. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000;61(suppl 2):20-25
11. Derogatis LR. Sexual function and quality of life: endpointsand outcomes. J Gend Specif Med 2001;4:35-42
12. Gelenberg AJ, Delgado P, Nurnberg HG. Sexual side effects of antidepressant drugs. Curr Psychiatry Rep 2000;2:223-227
13. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction; fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-194
14. Montejo AL, Llorca G, Izquierdo JA, et al. for the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001;62(suppl 3): 10-21
15. Davis R, Whittington R, Bryson HM. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997;53:608-636
16. Stahl SM. Basic psychopharmacology of antidepressants, pt 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998; 59(suppl 4):5-14
17. Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs 1999;57:607-631
18. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-880
19. Chalon SA, Granier LA, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in health subjects: a double-blind, controlled study. Neuropsychopharmacology 2003;28:1685-1693
20. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-315
21. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-390
22. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double- blind clinical trial. J Clin Psychiatry 2002;63:225-231
23. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002; 36:106-132
24. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399
25. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366
26. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
28. Eli Lilly and Company. Duloxetine versus placebo and paroxetine in the acute treatment of major depression, study group A trial results. Available at: http://www.lillytrials.com/results_files/cymbalta/ cymbalta_summary_4091a.pdf
29. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-470
30. Detke MJ, Wiltse CG, McNamara RK, et al. Duloxetine versus placebo and paroxetine in the acute and maintenance treatment of major depression. Presented at the 41st annual meeting of the American College of Neuropsychopharmacology; December 8-12, 2002; San Juan, Puerto Rico
31. Piazza LA, Markowitz JC, Kocsis JH, et al. Sexual functioning in chronically depressed patients treated with SSR1 antidepressants: a pilot study. Am J Psychiatry 1997;154:1757-1759
32. Kennedy SH, Eisfeld BS, Dickens SE, et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000;61:276-281
33. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997;58:532-537
34. Labbate LA, Grimes J, Mines A, et al. Sexual dysfunction induced by serotonin reuptake antidepressants. J Sex Marital Ther 1998;24:3-12
35. Michelson D, Schmidt M, Lee J, et al. Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment. J Sex Marital Ther 2001;27:289-302
36. Zajecka J, Dunner DL, Gelenberg AJ, et al. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. J Clin Psychiatry 2002;63: 709-716
37. Atmaca M, Kuloglu M, Tezcan E, et al. Switching to tianeptine in patients with antidepressant-induced sexual dysfunction. Hum Psychopharmacol 2003;18:277-280
38. Damis M, Patel Y, Simpson GM. Sildenafil in the treatment of SSRI-induced sexual dysfunction: a pilot study. Prim Care Companion J Clin Psychiatry 1999;1:184-187
39. Gelenberg AJ, Laukes C, McGahuey C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000;61:356-360
40. Westenberg HG, Stein DJ, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24: 49-55
41. Zourkova A, Hadasova E. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment. J Sex Marital Ther 2002;28:451-461